New data: HCQ reduces risk of eGFR decline by 61–73% & slows kidney function loss. Early initiation is critical for renal health in lupus nephritis.
2024 ACR Guideline for the Screening, Treatment & Management of Lupus Nephritis
Review 28 recommendations covering proteinuria screening, biopsy indications & triple therapy regimens for lupus nephritis.
3 AC&R Study Summaries: RA & Frailty, Hydroxychloroquine Can Protect Kidneys in Lupus Nephritis, & PT for Knee OA
Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.
Study: Reducing Cardiovascular Risks Helps Lupus Patients
Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.
10 Things to Know about Lupus
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
New Discoveries in Sjögren’s Disease Hold Promise
This article discusses advances in the diagnosis & treatment of Sjögren’s disease, as well as practical diagnostic tips for clinicians.
Risks of Severe HCQ Non-Adherence
Lower HCQ Serum Levels Associated with SLE Flare, Damage & Mortality Background & Objectives: Nguyen et al. set out to assess the consequences of severe non-adherence to hydroxychloroquine (HCQ) by measuring hydroxychloroquine serum levels, risks of systemic lupus erythematosus (SLE) flares, damage and mortality over five years of follow-up. Methods: The Systemic Lupus Erythematosus International…
Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri
At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.
New Study Probes Hydroxychloroquine Adherence During Pregnancy
Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…
ACR Insurance Subcommittee Tackles Known Issues
During a busy start to 2023, the ISC has been advocating with payers to address multiple coverage and reimbursement challenges facing rheumatology practices, including Cigna’s modifier 25 requirements, hydroxychloroquine access and coverage for apremilast combination therapy.
- 1
- 2
- 3
- 4
- Next Page »